Open Health said Acsel Health’s “deep industry expertise, scientific rigor and actionable analysis drives its success in providing valued partnership to life science companies”.

It added that its acquisition of Acsel Health complements its existing offering, broadening its range of services to pharma and biotech companies.

Rob Barker, chief executive of Open Health, said: “Acsel is an extraordinary addition to Open Health. Acsel’s expert team and long-standing client relationships significantly strengthen our ability to support the commercialisation of our clients’ assets and unlock access for patients.”

Lujing Wang, founder and managing partner of Acsel Health, which has more than 40 staff, said: “We are thrilled to join Open Health and to work with a wider team to solve today’s demands and meet tomorrow’s expectations for pharma and biotech customers. With new colleagues and capabilities to partner with, we are equipped to answer the most challenging cross-disciplinary questions in life science across all key therapeutic areas.”

Fairmount Partners acted as exclusive financial advisor to Acsel Health. The terms of the transaction were not disclosed.

European private equity firm Astorg acquired Open Health from Amulet Capital Partners last year.

The agency has more than 1,000 staff globally and more than than 170 clients, including almost all of the top 50 pharmaceutical companies.

The acquisition of Acsel Health is the latest in a series of deals by Open Health. In 2021 it acquired medical comms agency Spirit and digital creative agency Ark, and last year it bought US medical comms platform The CM Group from NaviMed Capital.

Established in 2011, and headquartered in London, Open Health claims to deliver “best-in-class scientific communications, health economics and outcomes research, and market access services.”

This article originally appeared on PRWeek US.